Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Sep;86(17):6719–6723. doi: 10.1073/pnas.86.17.6719

Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.

P G Natali 1, M R Nicotra 1, A Bigotti 1, I Venturo 1, L Marcenaro 1, P Giacomini 1, C Russo 1
PMCID: PMC297917  PMID: 2672003

Abstract

Analysis of surgical biopsies with monoclonal antibodies (mAbs) to framework determinants of major histocompatibility complex class I antigens has shown that malignant transformation is frequently associated with a marked loss of these cell surface molecules. The present study sought to determine whether more selective losses of major histocompatibility complex class I expression occur. Multiple specimens from 13 different types of primary and metastatic tumors were tested utilizing mAb BB7.2, which recognizes a polymorphic HLA-A2 epitope. In each case, expression of HLA-A,B,C molecules was determined by testing with mAb W6/32 directed to a framework HLA class I determinant. We have found that in HLA-A2-positive patients (identified by reactivity of their normal tissues with mAb BB7.2), HLA-A2 products are not detectable or are reduced in their expression in 70-80% of endometrial, colorectal, mammary, and renal tumors; in 40-60% of soft-tissue, skin, ovary, urinary bladder, prostate, and stomach tumors; and in 25-30% of melanomas and lung carcinomas tested. All tumors expressed the framework HLA-A,B,C determinant. The HLA-A2 epitope recognized by mAb BB7.2 is located in a portion of the HLA-A2 molecule postulated to react with the T-cell receptor. Immune surveillance to tumors is thought to depend on cytotoxic T cells, which require corecognition of polymorphic HLA class I epitopes, and on natural killer cells, which are, on the contrary, activated by the absence of HLA class I antigens. The selective loss of an HLA class I polymorphic epitope shown in this study may explain the mechanism by which tumor cells escape both T-cell recognition and natural killer cell surveillance.

Full text

PDF
6720

Images in this article

6720Image
on p.6720
6720Image
on p.6720
6720Image
on p.6720
6720Image
on p.6720
6722Image
on p.6722
6722Image
on p.6722
6722Image
on p.6722
6722Image
on p.6722
6722Image
on p.6722

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987 Oct 8;329(6139):506–512. doi: 10.1038/329506a0. [DOI] [PubMed] [Google Scholar]
  2. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987 Oct 8;329(6139):512–518. doi: 10.1038/329512a0. [DOI] [PubMed] [Google Scholar]
  3. Bodmer W. F. HLA structure and function: a contemporary view. Tissue Antigens. 1981 Jan;17(1):9–20. doi: 10.1111/j.1399-0039.1981.tb00661.x. [DOI] [PubMed] [Google Scholar]
  4. Bonner W. M., Laskey R. A. A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem. 1974 Jul 1;46(1):83–88. doi: 10.1111/j.1432-1033.1974.tb03599.x. [DOI] [PubMed] [Google Scholar]
  5. Csiba A., Whitwell H. L., Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer. 1984 Nov;50(5):699–709. doi: 10.1038/bjc.1984.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doyle A., Martin W. J., Funa K., Gazdar A., Carney D., Martin S. E., Linnoila I., Cuttitta F., Mulshine J., Bunn P. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985 May 1;161(5):1135–1151. doi: 10.1084/jem.161.5.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fossati G., Anichini A., Parmiani G. Melanoma cell lysis by human CTL clones: differential involvement of T3, T8 and HLA antigens. Int J Cancer. 1987 Jun 15;39(6):689–694. doi: 10.1002/ijc.2910390606. [DOI] [PubMed] [Google Scholar]
  8. Giacomini P., Aguzzi A., Tecce R., Fisher P. B., Ferrone S. A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon-treated human melanoma cells. Eur J Immunol. 1985 Sep;15(9):946–951. doi: 10.1002/eji.1830150915. [DOI] [PubMed] [Google Scholar]
  9. Harel-Bellan A., Quillet A., Marchiol C., DeMars R., Tursz T., Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci U S A. 1986 Aug;83(15):5688–5692. doi: 10.1073/pnas.83.15.5688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Katzav S., De Baetselier P., Tartakovsky B., Feldman M., Segal S. Alterations in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from nonmetastatic to metastatic cells. J Natl Cancer Inst. 1983 Aug;71(2):317–324. [PubMed] [Google Scholar]
  11. Kärre K., Ljunggren H. G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986 Feb 20;319(6055):675–678. doi: 10.1038/319675a0. [DOI] [PubMed] [Google Scholar]
  12. Momburg F., Degener T., Bacchus E., Moldenhauer G., Hämmerling G. J., Möller P. Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer. 1986 Feb 15;37(2):179–184. doi: 10.1002/ijc.2910370203. [DOI] [PubMed] [Google Scholar]
  13. Mottolese M., Venturo I., Donnorso R. P., Curcio C. G., Rinaldi M., Natali P. G. Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1277–1284. doi: 10.1016/0277-5379(88)90215-5. [DOI] [PubMed] [Google Scholar]
  14. Möller P., Herrmann B., Moldenhauer G., Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer. 1987 Jul 15;40(1):32–39. doi: 10.1002/ijc.2910400107. [DOI] [PubMed] [Google Scholar]
  15. Natali P. G., Bigotti A., Nicotra M. R., Viora M., Manfredi D., Ferrone S. Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 1984 Oct;44(10):4679–4687. [PubMed] [Google Scholar]
  16. Natali P. G., Giacomini P., Bigotti A., Imai K., Nicotra M. R., Ng A. K., Ferrone S. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res. 1983 Feb;43(2):660–668. [PubMed] [Google Scholar]
  17. Piontek G. E., Taniguchi K., Ljunggren H. G., Grönberg A., Kiessling R., Klein G., Kärre K. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol. 1985 Dec;135(6):4281–4288. [PubMed] [Google Scholar]
  18. Rees R. C., Buckle A. M., Gelsthorpe K., James V., Potter C. W., Rogers K., Jacob G. Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br J Cancer. 1988 Apr;57(4):374–377. doi: 10.1038/bjc.1988.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Roberts T. E., Shipton U., Moore M. Role of MHC class-I antigens and the CD3 complex in the lysis of autologous human tumours by T-cell clones. Int J Cancer. 1987 Apr 15;39(4):436–441. doi: 10.1002/ijc.2910390404. [DOI] [PubMed] [Google Scholar]
  20. Russo C., Callegaro L., Lanza E., Ferrone S. Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods. 1983 Dec 16;65(1-2):269–271. doi: 10.1016/0022-1759(83)90324-1. [DOI] [PubMed] [Google Scholar]
  21. Russo C., Ng A. K., Pellegrino M. A., Ferrone S. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics. 1983;18(1):23–35. doi: 10.1007/BF00401353. [DOI] [PubMed] [Google Scholar]
  22. Schrier P. I., Bernards R., Vaessen R. T., Houweling A., van der Eb A. J. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. 1983 Oct 27-Nov 2Nature. 305(5937):771–775. doi: 10.1038/305771a0. [DOI] [PubMed] [Google Scholar]
  23. Smith M. E., Bodmer W. F., Bodmer J. G. Selective loss of HLA-A,B,C locus products in colorectal adenocarcinoma. Lancet. 1988 Apr 9;1(8589):823–824. doi: 10.1016/s0140-6736(88)91682-0. [DOI] [PubMed] [Google Scholar]
  24. Tanaka K., Isselbacher K. J., Khoury G., Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 1985 Apr 5;228(4695):26–30. doi: 10.1126/science.3975631. [DOI] [PubMed] [Google Scholar]
  25. Wallich R., Bulbuc N., Hämmerling G. J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985 May 23;315(6017):301–305. doi: 10.1038/315301a0. [DOI] [PubMed] [Google Scholar]
  26. van den Ingh H. F., Ruiter D. J., Griffioen G., van Muijen G. N., Ferrone S. HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer. 1987 Feb;55(2):125–130. doi: 10.1038/bjc.1987.26. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES